"Glioblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Descriptor ID |
D005909
|
| MeSH Number(s) |
C04.557.465.625.600.380.080.335 C04.557.470.670.380.080.335 C04.557.580.625.600.380.080.335
|
| Concept/Terms |
Glioblastoma- Glioblastoma
- Glioblastomas
- Astrocytoma, Grade IV
- Astrocytomas, Grade IV
- Grade IV Astrocytoma
- Grade IV Astrocytomas
Giant Cell Glioblastoma- Giant Cell Glioblastoma
- Giant Cell Glioblastomas
- Glioblastoma, Giant Cell
- Glioblastomas, Giant Cell
|
Below are MeSH descriptors whose meaning is more general than "Glioblastoma".
Below are MeSH descriptors whose meaning is more specific than "Glioblastoma".
This graph shows the total number of publications written about "Glioblastoma" by people in this website by year, and whether "Glioblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 1 | 3 | 4 |
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 1 | 3 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 4 | 0 | 4 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 1 | 4 |
| 2006 | 1 | 1 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 3 | 1 | 4 |
| 2010 | 10 | 2 | 12 |
| 2011 | 4 | 5 | 9 |
| 2012 | 12 | 0 | 12 |
| 2013 | 8 | 3 | 11 |
| 2014 | 13 | 0 | 13 |
| 2015 | 13 | 3 | 16 |
| 2016 | 8 | 0 | 8 |
| 2017 | 14 | 0 | 14 |
| 2018 | 14 | 1 | 15 |
| 2019 | 12 | 1 | 13 |
| 2020 | 10 | 1 | 11 |
| 2021 | 8 | 0 | 8 |
| 2022 | 10 | 0 | 10 |
| 2023 | 12 | 1 | 13 |
| 2024 | 10 | 0 | 10 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glioblastoma" by people in Profiles.
-
Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion. Oncologist. 2025 Jan 17; 30(1).
-
Discontiguous recurrences of IDH-wildtype glioblastoma share a common origin with the initial tumor and are frequently hypermutated. Acta Neuropathol Commun. 2025 Jan 16; 13(1):9.
-
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. Neuro Oncol. 2025 Jan 12; 27(1):89-105.
-
Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy? Neuro Oncol. 2025 Jan 12; 27(1):33-49.
-
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial. JAMA Oncol. 2024 Dec 01; 10(12):1637-1644.
-
Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas. Viruses. 2024 Nov 14; 16(11).
-
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. Neuro Oncol. 2024 Nov 04; 26(11):2044-2060.
-
Analysis of DNA Methylation in Gliomas: Assessment of Preanalytical Variables. Lab Invest. 2024 Dec; 104(12):102160.
-
Temozolomide use in elderly patients with MGMT promoter unmethylated glioblastoma: Is it finally time to dismount a dead horse? Neuro Oncol. 2024 Oct 03; 26(10):1876-1877.
-
Dual targeting macrophages and microglia is a therapeutic vulnerability in models of PTEN-deficient glioblastoma. J Clin Invest. 2024 Oct 01; 134(22).